SCHEMBL9069333

SCHEMBL9069333

c1ccc(-c2nc(-c3ccccn3)nc(N3CCNCC3)n2)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 2/20 0.59
▸ TDP1 Q9NUW8 4/20 0.58
▸ KDM4E B2RXH2 3/20 0.58
▸ ALDH1A1 P00352 2/20 0.56
▸ PLD1 Q13393 1/20 0.56
▸ HTR1A P08908 1/20 0.55
▸ KMT2A Q03164 3/20 0.48
▸ POLB P06746 1/20 0.48
▸ L3MBTL1 Q9Y468 3/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ HRH1 P35367 1/20 0.46
▸ CETP P11597 1/20 0.46
▸ METAP1 P53582 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ ROCK1 Q13464 1/20 0.45
▸ HTR2C P28335 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1-Hexanol SCHEMBL9689224 0.84 FLT3 (0.48) HTR7TDP1KDM4EALDH1A1PLD1
SCHEMBL9226047 0.82 TDP1 (0.60) TDP1KDM4EALDH1A1KMT2APOLB
SCHEMBL9069327 0.82 PLD1 (0.58) HTR7TDP1KDM4EALDH1A1PLD1
SCHEMBL10974393 0.79 KMT2A (0.60) HTR7TDP1KDM4EALDH1A1PLD1
SCHEMBL9073239 0.79 HTR7 (0.54) HTR7KDM4EALDH1A1PLD1HTR1A
SCHEMBL3766351 0.78 HTR7 (0.52) HTR7TDP1KDM4EALDH1A1PLD1
SCHEMBL30422841 0.78 KDM4E (0.53) HTR7KDM4EALDH1A1PLD1HTR1A
Hydrochloric Acid SCHEMBL11161534 0.78 KMT2A (0.58) HTR7TDP1KDM4EALDH1A1HTR1A
SCHEMBL1308549 0.77 METAP1 (0.64) TDP1KDM4EALDH1A1KMT2APOLB
SCHEMBL322756 0.76 KDM4E (1.00) TDP1KDM4EALDH1A1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0238545-B1 C20 THROUGH C26 AMINO STEROIDS UPJOHN CO (US) 1995-11-15 — — EP claimed
EP-0263213-B1 C20 Through C26 amino steroids UPJOHN CO (US) 1995-09-06 — — EP claimed
US-5268477-A Containing a pyrrolidine or pyridine ring structure THE UPJOHN COMPANY (US) 1993-12-07 — — US claimed
EP-0238545-A1 C 20? THROUGH C 26? AMINO STEROIDS. UPJOHN CO (US) 1987-09-30 — — EP claimed
WO-1987001706-A2 C20 THROUGH C26 AMINO STEROIDS THE UPJOHN COMPANY (US) 1987-03-26 — — WO claimed
US-5506354-A ANTIULCER, ANTITURMOR, ANTIARTHRITIC, ANTIATHEROSCLEROSIS, ANTIALLERGIC, ANTIASTHMA AGENTS THE UPJOHN COMPANY (US) 1996-04-09 — — US disclosed
EP-0238545-B1 C20 THROUGH C26 AMINO STEROIDS UPJOHN CO (US) 1995-11-15 — — EP disclosed
US-RE35053-E Intermediates for amino substituted steroids THE UPJOHN COMPANY (US) 1995-10-10 — — US disclosed
EP-0263213-B1 C20 Through C26 amino steroids UPJOHN CO (US) 1995-09-06 — — EP disclosed
US-5382661-A Useful in treating spinal trauma, head injury, subarachnoid hemorrhage THE UPJOHN COMPANY (US) 1995-01-17 — — US disclosed
US-5380841-A Steroids as antiinflammatory agents THE UPJOHN COMPANY (US) 1995-01-10 — — US disclosed
US-5380839-A Antitumor agents, antisecretory agents, enzyme inhibitors or antiasthmatics THE UPJOHN COMPANY (US) 1995-01-10 — — US disclosed
EP-0358676-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1990-03-21 — — EP disclosed
EP-0354920-A1 AMINO-9,10-SECOSTEROIDS THE UPJOHN COMPANY (US) 1990-02-21 — — EP disclosed
EP-0293078-A1 Pharmaceutically active amines THE UPJOHN COMPANY (US) 1988-11-30 — — EP disclosed
WO-1988008424-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1988-11-03 — — WO disclosed
WO-1988007527-A1 AMINO-9,10-SECOSTEROIDS THE UPJOHN COMPANY (US) 1988-10-06 — — WO disclosed
EP-0263213-A1 C20 Through C26 amino steroids THE UPJOHN COMPANY (US) 1988-04-13 — — EP disclosed
EP-0238545-A1 C 20? THROUGH C 26? AMINO STEROIDS. UPJOHN CO (US) 1987-09-30 — — EP disclosed
WO-1987001706-A2 C20 THROUGH C26 AMINO STEROIDS THE UPJOHN COMPANY (US) 1987-03-26 — — WO disclosed
Send feedback